Titre : | A Cautionary Note on the Evaluation of Biomarkers of Subtypes of a Single Disease. (2008) |
Auteurs : | ADEWALE (Adeniyi-J) : USA. Merck Research Laboratories. North Wales. PA. ; Irina DINU ; LAMPE (Paul-D) : USA. Fred Hutchinson Cancer Research Center. Seattle. WA. ; MITCHELL (Bree-L) : USA. Biomedical Life Sciences Group. Intel Corporation. Santa Clara. CA. ; . QI LIU ; Yutaka YASUI ; Department of Public Health Sciences. School of Public Health. University of Alberta. Edmonton. AB. CAN |
Type de document : | Article |
Dans : | American journal of epidemiology (vol. 168, n° 6, 2008) |
Pagination : | 559-562 |
Langues: | Anglais |
Mots-clés : | Evaluation ; Pathologie ; Classification maladies ; Classification ; Probabilité ; Epidémiologie ; Homme ; Examen complémentaire |
Résumé : | [BDSP. Notice produite par INIST-CNRS R0xtqD7p. Diffusion soumise à autorisation]. Heterogeneity in the molecular characteristics of a disease presents a challenge to investigators attempting to identify biomarkers of the disease. Preceding the biomarker discovery effort with stratification within a heterogeneous disease group, which amounts to grouping disease cases into more homogeneous subtypes, seems to be a natural strategy for discovering subtype-specific biomarkers. This is because biologically more homogeneous subgroups are presumably easier to distinguish from the nondiseased than the entire heterogeneous disease group. The misleading benefits of this two-step approach are illustrated using an example from a protein biomarker discovery project for breast cancer. A potential analytical pitfall in this framework is explained using a conditional probability argument. |